Investigation of the cardioprotective effects of *Crataegus oxycantha* and its molecular mechanism

Harshul Parikh PhD1, CB Tripathi MD2, Prakash Shah PhD1, Vijay Ghori M Pharm1, Ramesh K Goyal PhD3


**BACKGROUND:** *Crataegus oxycantha* has been used as a cardiotonic for the treatment of early stage congestive heart failure; however, there are few authentic investigational studies addressing its cardioprotective use.

**OBJECTIVE:** To investigate the cardioprotective effect of *C. oxycantha* and to elucidate its possible mechanism of action.

**METHODS:** The effects of *C. oxycantha* were studied using a rat model of isoproterenol (ISO) (100 mg/kg subcutaneous for two days) - induced myocardial necrosis. Cardiac damage was assessed using various biochemical enzymes and histological studies. Various oxidative parameters and Na+-K+ ATPase activity were studied to elucidate the mechanism of action.

**RESULTS:** Pretreatment with *C. oxycantha* significantly prevented the increase in serum levels of cardiac troponin-I, creatine kinase-MB, lactate dehydrogenase, glutamate oxidoreductase, glutamate pyruvate transaminase and uric acid in ISO-treated (100 mg/kg) rats. The increased serum levels of cholesterol, triglyceride, low-density lipoprotein cholesterol and atherogenic index after ISO administration were decreased to nearly normal levels by *C. oxycantha* extract. Pretreatment with *C. oxycantha* in ISO-treated animals produced significant decrease in lipid peroxidation and significant increase in endogenous antioxidant superoxide dismutase, catalase and reduced glutathione in myocardial tissue. *C. oxycantha* extract significantly inhibited Na+-K+ ATPase enzyme present in heart homogenate by virtue of presence of ursolic acid as evidenced by high-performance thin layer chromatography analysis of *C. oxycantha* extract, which may be a possible mechanism of cardiotonic activity of *C. oxycantha*.

**CONCLUSION:** *C. oxycantha* may be viewed as potentially cardiotonic, cardioprotective and antioxidant.

**Key Words:** Cardiotoxic; Cardiac troponin-I; Na+-K+ ATPase; Uric acid

**METHODS**

**Materials**

Isoproterenol (ISO) and digoxin were purchased from Sigma-Aldrich. *C. oxycantha* mother tincture of SBL Homeopathic, Delhi was purchased and used for the present study. All reagents and chemicals used in the present study were of analytical grade. Standard enzymatic kits for estimation of serum parameters were commercially purchased. Albino Wistar rats were purchased from Cadila Pharmaceuticals, Dholka, India.

**Animals**

All experiments in the present study were performed on healthy adult Wistar rats of either sex (weight 250 g to 300 g), obtained from in house animal breeding. They were housed in polycarbonate cages lined with husk, renewed every 24 h under 12:12 h light dark cycle. They were kept in a temperature-controlled (25°C) facility and had ad libitum access to food and water. During the experimental period, the animals were fed with standard laboratory diet (Pranav agro industries Ltd, Maharashtra, India).

All experiments and protocols described in the present study were approved by the Institutional Animal Ethics Committee (IAEC) of Government Medical College, Bhavnagar vide permission letter no. IAEC no. 10/2009, amendment no. 02/2011 dated September 13, 2011, and were performed according to the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals, ministry of social justice and empowerment, government of India, New Delhi.
Phytochemical analysis of C. oxycantha extract

Total phenolic and flavonoid content of Crataegus oxycantha

<table>
<thead>
<tr>
<th>Group</th>
<th>BW, g</th>
<th>HW, g</th>
<th>HW/BW ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>288.3±6.15</td>
<td>0.69±0.004</td>
<td>0.0024</td>
</tr>
<tr>
<td>Control + C. oxycantha (50 mg/kg body weight orally)</td>
<td>274.2±4.36</td>
<td>0.68±0.004</td>
<td>0.0025</td>
</tr>
<tr>
<td>ISO (100 mg/kg)</td>
<td>223.3±5.43*</td>
<td>0.93±0.005*</td>
<td>0.0042*</td>
</tr>
<tr>
<td>ISO (100 mg/kg + C. oxycantha 25 mg/kg body weight orally)</td>
<td>252.5±6.16†</td>
<td>0.77±0.006†</td>
<td>0.0030†</td>
</tr>
<tr>
<td>ISO (100 mg/kg + C. oxycantha 50 mg/kg body weight orally)</td>
<td>279.2±3.52‡</td>
<td>0.70±0.012‡</td>
<td>0.0025‡</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD unless otherwise indicated. *Significantly different from control (P<0.05); †Significantly different from isoproterenol (ISO)-treated group (P<0.05); ‡Significantly different from C. oxycantha 25 mg/kg (P<0.05)

Collection of blood samples and separation of serum

Blood samples were drawn from the retroorbital plexus under light ether anesthesia without anticoagulant at day 30 of treatment. The serum was separated and used for biochemical analysis. In vitro quantitative measurement of serum cardiac troponin-I (cTnI) was performed using the Tosoh AIA system analyzer, which was based on an immunofluorescent assay. Serum CK-MB, LDH, SGOT, SGPT, uric acid, total cholesterol, triglyceride and high-density lipoprotein (HDL) cholesterol were estimated using commercially available standard biochemical kits. Low-density lipoprotein (LDL) cholesterol and atherogenic index were determined using a standard formula.

Estimation of fecal cholesterol

Lipids were extracted from feces by the procedure developed by Folch et al (5). Briefly, the fecal matter solution (20% w/v) was prepared in a chloroform:methanol (2:1) mixture. The lipids were extracted by mixing 1 volume of fecal matter solution with 4 volumes of chloroform:methanol mixture. It was then vortexed and centrifuged at 3000 rpm for 5 min. The lower organic phase containing lipids was transferred to another tube and the extraction procedure was repeated. To this solution, 0.2 mL of magnesium chloride (0.017%) per mL of organic extract was added, vortexed and centrifuged. The lower phase was transferred and evaporated. The dried lipid residues were dissolved in solution of 0.1% Triton X-100 in chloroform. The resultant solution was then evaporated to dryness and dried residue was used to estimate total cholesterol.

Experimental design

The effect of C. oxycantha was studied using an ISO-induced myocardial necrosis rat model. Albino Wistar rats were subcutaneously injected with ISO 100 mg/kg on two consecutive days at an interval of 24 h to induce myocardial toxicity. The animals were randomly assigned to five groups as follows. Group I (normal control) animals received normal food and water ad libitum everyday for 30 days and injected 0.9% w/v normal saline for two consecutive days at an interval of 24 h. Group II (diseased control) animals received ISO 100 mg/kg was subcutaneously injected for two consecutive days at an interval of 24 h. Group III (Normal control + C. oxycantha extract) animals received C. oxycantha extract 50 mg/kg/day orally administered for 30 days. Group IV (diseased control + C. oxycantha extract 25 mg/kg) animals subcutaneously injected ISO 100 mg/kg for two consecutive days at an interval of 24 h after oral pretreatment with C. oxycantha extract 25 mg/kg/day for 30 days. Group V (diseased control + C. oxycantha extract 50 mg/kg) animals subcutaneously injected with ISO 100 mg/kg for two consecutive days at an interval of 24 h after oral pretreatment with C. oxycantha extract 50 mg/kg/day for 30 days.

Standardization of C. oxycantha dose

A pilot study was performed to establish the optimum dose of C. oxycantha that exhibited maximum cardioprotective effect during the 30-day treatment period. It was found that 25 mg/kg/day and 50 mg/kg/day doses of C. oxycantha were more effective in functional recovery of biochemical alterations, and were selected for further evaluation in the present study.

Collection of blood samples and separation of serum

Blood samples were drawn from the retroorbital plexus under light ether anesthesia without anticoagulant at day 30 of treatment. The serum was separated and used for biochemical analysis. In vitro quantitative measurement of serum cardiac troponin-I (cTnI) was performed using the Tosoh AIA system analyzer, which was based on an immunofluorescent assay. Serum CK-MB, LDH, SGOT, SGPT, uric acid, total cholesterol, triglyceride and high-density lipoprotein (HDL) cholesterol were estimated using commercially available standard biochemical kits. Low-density lipoprotein (LDL) cholesterol and atherogenic index were determined using a standard formula.

Estimation of fecal cholesterol

Lipids were extracted from feces by the procedure developed by Folch et al (5). Briefly, the fecal matter solution (20% w/v) was prepared in a chloroform:methanol (2:1) mixture. The lipids were extracted by mixing 1 volume of fecal matter solution with 4 volumes of chloroform:methanol mixture. It was then vortexed and centrifuged at 3000 rpm for 5 min. The lower organic phase containing lipids was transferred to another tube and the extraction procedure was repeated. To this solution, 0.2 mL of magnesium chloride (0.017%) per mL of organic extract was added, vortexed and centrifuged. The lower phase was transferred and evaporated. The dried lipid residues were dissolved in solution of 0.1% Triton X-100 in chloroform. The resultant solution was then evaporated to dryness and dried residue was used to estimate total cholesterol.

Experimental design

The effect of C. oxycantha was studied using an ISO-induced myocardial necrosis rat model. Albino Wistar rats were subcutaneously injected with ISO 100 mg/kg on two consecutive days at an interval of 24 h to induce myocardial toxicity. The animals were randomly assigned to five groups as follows. Group I (normal control) animals received normal food and water ad libitum everyday for 30 days and injected 0.9% w/v normal saline for two consecutive days at an interval of 24 h. Group II (diseased control) animals received ISO 100 mg/kg was subcutaneously injected for two consecutive days at an interval of 24 h. Group III (Normal control + C. oxycantha extract) animals received C. oxycantha extract 50 mg/kg/day orally administered for 30 days. Group IV (diseased control + C. oxycantha extract 25 mg/kg) animals subcutaneously injected ISO 100 mg/kg for two consecutive days at an interval of 24 h after oral pretreatment with C. oxycantha extract 25 mg/kg/day for 30 days. Group V (diseased control + C. oxycantha extract 50 mg/kg) animals subcutaneously injected with ISO 100 mg/kg for two consecutive days at an interval of 24 h after oral pretreatment with C. oxycantha extract 50 mg/kg/day for 30 days.

Standardization of C. oxycantha dose

A pilot study was performed to establish the optimum dose of C. oxycantha that exhibited maximum cardioprotective effect during the 30-day treatment period. It was found that 25 mg/kg/day and 50 mg/kg/day doses of C. oxycantha were more effective in functional recovery of biochemical alterations, and were selected for further evaluation in the present study.

Collection of blood samples and separation of serum

Blood samples were drawn from the retroorbital plexus under light ether anesthesia without anticoagulant at day 30 of treatment. The serum was separated and used for biochemical analysis. In vitro quantitative measurement of serum cardiac troponin-I (cTnI) was performed using the Tosoh AIA system analyzer, which was based on an immunofluorescent assay. Serum CK-MB, LDH, SGOT, SGPT, uric acid, total cholesterol, triglyceride and high-density lipoprotein (HDL) cholesterol were estimated using commercially available standard biochemical kits. Low-density lipoprotein (LDL) cholesterol and atherogenic index were determined using a standard formula.

Estimation of fecal cholesterol

Lipids were extracted from feces by the procedure developed by Folch et al (5). Briefly, the fecal matter solution (20% w/v) was prepared in a chloroform:methanol (2:1) mixture. The lipids were extracted by mixing 1 volume of fecal matter solution with 4 volumes of chloroform:methanol mixture. It was then vortexed and centrifuged at 3000 rpm for 5 min. The lower organic phase containing lipids was transferred to another tube and the extraction procedure was repeated. To this solution, 0.2 mL of magnesium chloride (0.017%) per mL of organic extract was added, vortexed and centrifuged. The lower phase was transferred and evaporated. The dried lipid residues were dissolved in solution of 0.1% Triton X-100 in chloroform. The resultant solution was then evaporated to dryness and dried residue was used to estimate total cholesterol.
TABLE 3
Effect of *Crataegus oxycantha* on serum levels of cardiac troponin-I (cTN-I), creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH)

<table>
<thead>
<tr>
<th>Groups</th>
<th>cTN-I, IU/L</th>
<th>CK-MB, IU/L</th>
<th>LDH, IU/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.02</td>
<td>610.5±27.36</td>
<td>172.3±15.00</td>
</tr>
<tr>
<td>Control + <em>C. oxycantha</em></td>
<td>0.02</td>
<td>560.4±12.08</td>
<td>174.6±7.54</td>
</tr>
<tr>
<td>ISO (100 mg/kg)</td>
<td>1.54±0.62*</td>
<td>862.9±17.50*</td>
<td>278.2±17.43*</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 25 mg/kg body weight orally)</td>
<td>0.037±0.02†</td>
<td>684.5±10.84†</td>
<td>233.8±12.00†</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 50 mg/kg body weight orally)</td>
<td>0.02†</td>
<td>590.8±14.92†</td>
<td>198.2±9.28†</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD unless otherwise indicated. *Significantly different from control (P<0.05); †Significantly different from isoproterenol (ISO)-treated group (P<0.05); ‡Significantly different from *C. oxycantha* 25 mg/kg (P<0.05)

Collection of cardiac tissue

Rats were euthanized and the hearts were dissected after collection of serum. The dissected hearts were used for tissue biochemical analysis and histopathological study. Lipid peroxidation (LPO) in terms of malondialdehyde and superoxide dismutase (SOD) were estimated using the method described by Slater and Sawyer (6) and Mishra and Fridovich (7), respectively. Levels of reduced glutathione (GSH) were estimated according to the method of Morani et al (8). Catalase was estimated according to the method described by Hugo (9). Na⁺⁻K⁺-ATPase activity was assayed according to the method described by Bonting (10).

Histological examination was performed on myocardial tissue. Briefly, blood-free sections of myocardial tissue were fixed in bovine's fluid (picric acid:formalin:acetic acid [75:25:5]) and were washed thoroughly in repeated changes of 70% alcohol. The dehydrated sections were treated with toluene:xylene (50:50) and embedded in paraffin wax. The embedded cardiac tissue was serially cut in horizontal plane on a Leitz microtome to obtain 5 µm to 15 µm thick sections, which were mounted on glass slides with egg albumin in glycerin solution (50% v/v). They were then stained with 10% hematoxylin which were mounted on glass slides with egg albumin in glycerin solution (50% v/v). They were then stained with 10% hematoxylin and 1% eosin for 2 min followed by treatment with 10% eosin for 3 min to 5 min followed by treatment with 10% eosin for 3 min to 5 min followed by treatment with 10% eosin for 3 min to 5 min. The sections were viewed under 40× magnification.

RESULTS

Phytochemical analysis

The extracts of *C. oxycantha* was analyzed for total phenolic and total flavonoids content, and antioxidant potential. The total phenolic and total flavonoids content of *C. oxycantha* were 75.2 mg Gallic acid equivalents and 26 mg Rutin equivalents per gram dry weight, respectively (Table 1).

The in vitro evaluation of antioxidant activity of *C. oxycantha* was performed using the DPPH (1,1-Diphenyl-2-picrylhydrazyl) assay. The free-radical scavenging activity of *C. oxycantha* was 62.04%, as reported in Table 1. In HPTLC analysis, comparison of the spectral characteristic of the peaks of standards (ursolic acid) and sample revealed the identity of standards (ursolic acid) in the *C. oxycantha* extract. The *C. oxycantha* extract was able to reduce the ursolic acid content of the developing solvent system using the mobile phase, which produced good separation, with Rf value 0.91. The standard ursolic acid Rf value was 0.91. The content of ursolic acid in the investigative *C. oxycantha* extract was quantitatively analyzed by linear regression and was found to be 0.3 µg/mL (Figures 1 and 2).

Effect of *C. oxycantha* on cardiac biomarkers

A statistically significant (ie, P<0.05) increase in heart weight:body weight ratio was found in ISO-treated rats compared with the control group. *C. oxycantha* was found to prevent significant increase in this ratio (Table 2). Serum cTnI and CK-MB are crucial biomarkers for myocardial damage, which were found to be significantly increased (P<0.05) after ISO treatment in rats compared with control. Administration of *C. oxycantha* produced significant reduction (P<0.05) in serum cTnI, CK-MB and LDH levels compared with the ISO-treated group, thus exhibiting prevention of cardiac damage produced by myocardial ischemia. The reduction in CK-MB level produced by *C. oxycantha* was dose dependent (Table 3). Subcutaneous administration of ISO produced significant (P<0.05) increase in serum SGOT, SGPT and uric acid levels in rats compared with control. *C. oxycantha* (in both the doses) significantly (P<0.05) prevented the increase in serum level of these parameters compared with the ISO group (Table 4).

Effect of *C. oxycantha* on lipid parameters

Serum cholesterol and triglyceride level in ISO-treated rats were significantly (P<0.05) increased compared with control. After treatment with *C. oxycantha* at both the doses, there were significant reductions (P<0.05) in cholesterol and triglyceride level in a dose-dependent manner. However, there were no significant changes observed in HDL cholesterol level in ISO-treated animals as well as in *C. oxycantha*-treated groups (Table 5).

Significant (P<0.05) increase in serum LDL cholesterol and very low LDL (VLDL) cholesterol level were found in ISO-treated rats compared with control. Treatment with *C. oxycantha* at both the doses significantly (P<0.05) prevented increases in serum LDL cholesterol and VLDL cholesterol level compared with ISO and the effect was also significantly dose dependent. There was also a significant (P<0.05) increase in the atherogenic index in ISO-treated rats, which was significantly (P<0.05) prevented by higher dose of *C. oxycantha*; however, the result was not significant at the lower dose. *C. oxycantha* extract produced a significant (P<0.05) increase in fecal cholesterol
excretion. The differences in cholesterol excretion were significant \((P<0.05)\) at two test doses of *Coxycantha* extract. Positive changes in the above parameters reflect prevention of atherogenesis (Table 6).

**Effect of *Coxycantha* oxidative stress in myocardial tissue**

Administration of ISO in rats produced significant \((P<0.05)\) increases in malondialdehyde levels, a product of LPO in heart homogenate compared with control. Pretreatment with *Coxycantha* at both doses was found to prevent significant increases in malondialdehyde levels \((P<0.05)\). There was significant \((P<0.05)\) reduction in SOD, catalase and GSH levels in heart homogenates of ISO-treated rats, which were significantly \((P<0.05)\) prevented after treatment at both the doses of *Coxycantha* extract as reported in Table 7.

**Effect of *Coxycantha* on Na\(^+\)/K\(^+\) ATPase enzyme in myocardial tissue**

*Coxycantha* has been reported to possess positive inotropic properties, which may be due to inhibition of Na\(^+\)/K\(^+\) ATPase enzyme. The result suggested that *Coxycantha* produced significant dose-dependent inhibition of Na\(^+\)/K\(^+\) ATPase enzyme present in heart homogenates of rats (Figure 3).

Standard drug digoxin also produced significant dose-dependent reduction in myocardial Na\(^+\)/K\(^+\) ATPase enzyme activity in heart homogenates of rats; however, compared with *Coxycantha* (in milligram concentration), digoxin produced a nearly similar extent of Na\(^+\)/K\(^+\) ATPase enzyme inhibition in microgram (µg) concentration (Figure 4).

**DISCUSSION**

Antioxidants, such as flavonoids, polyphenols, tannins and anthocyanins, and certain vitamins are gaining more importance in the prevention of chronic conditions such as cardiovascular disease, diabetes and atherosclerosis. It was also reported that *Coxycantha* possess potent antioxidants such as vitamin C, many flavanoids, oligomeric procyanidin-epicatechol, cardiotonic amines, tannins, saponins and triterpene acid (11). In the present study, *Coxycantha* extract showed the presence of rich content of total flavonoids and phenolic compounds, which may be responsible for their strong antioxidant efficacy. The in vitro DPPH (1,1-diphenyl-2-picrylhydrazyl) assay is preferably and widely used to assess free-radical scavenging activity of antioxidant vitamins and plant extracts (12). In our investigation, the DPPH assay of *Coxycantha* produced significant free radical scavenging activity (62.04\%) by reducing the stable DPPH radicals, which may be attributed to rich content of total phenolics and flavanoids present in the extract.

The HPTLC method is the most precise and reliable method for qualitative and quantitative estimation of different phytoconstituents present in plant extracts. In our qualitative analysis, the HPTLC
chromatogram exhibited clearly resolution peak of terpenoid-ursolic acid present in investigative C oxycantha extract. Quantitative analysis using HPTLC also showed that rich amounts of ursolic acid is present in C oxycantha extract.

The rat model of ISO-induced myocardial necrosis, among many well known models, has often been used to evaluate several cardiac dysfunctions (13). The pathophysiological changes following ISO administration are comparable with those occurring in human myocardial alterations (14). Milei et al (15) reported that the myocardial lesions in rats induced by ISO may be due to action on the sarcolemma, stimulation of adenylate cyclase, activation of Na+ and Ca2+ channel, increase of calcium inflow and energy consumption leading to myocardial cellular death. In this context, Dhalla et al (16) reported that excessive catecholamine may affect transport mechanism of calcium primarily via oxidation reactions involving free radical-mediated damage and, hence, antioxidants may be indicated for stress induced myocardial damage. When myocardial cells are damaged or destroyed due to the deficiency of oxygen supply or glucose, the cell membrane becomes permeable or may rupture and results in the leakage of these enzymes into serum (15). In our investigation, we also found a significant increase in serum levels of LDH, SGOT and SGPT in ISO-treated rats. The reduction in serum level of all above cardiac biomarkers indicates prevention of myocardial damage and maintenance of myocardial cell integrity by C oxycantha.

The assay of activity of CK-MB isoenzyme in serum is a specific and useful index in the diagnosis of myocardial damage and subsequent infarction because of the marked abundance of this enzyme in heart and virtual absence from most of other tissues (22). The presence of CK-MB and LDH in heart tissue homogenate indicates myocardial integrity, while, their increased serum level after the release from heart tissue signifies myocardial injury (23). In the present study, serum CK-MB level was significantly increased in ISO-treated rats, which suggests the myocardial injury and loss of myocardial membrane integrity. Pretreatment with C oxycantha produced significant reduction in serum CK-MB level in ISO-treated rats.

Wittveen et al (24) reported that LDH, serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) enzymes levels in serum are supportive diagnostic marker of myocardial damage. When myocardial cells are damaged or destroyed due to the deficiency of oxygen supply or glucose, the cell membrane becomes permeable or may rupture and results in the leakage of these enzymes into serum (15). In our investigation, we also found a significant increase in serum levels of LDH, SGOT and SGPT in ISO-treated rats, which were decreased to significant level in C oxycantha pretreated rats. The reduction in serum level of all above cardiac biomarkers indicates prevention of myocardial damage and maintenance of myocardial cell integrity by C oxycantha.

Weir et al (25) reported that serum uric acid is considered to be a risk factor in the development of myocardial infarction. In ischemic condition, tissue becomes hypoxic and, consequently, ATP depletion occurs, which causes accumulation of hypoxanthine. Xanthine oxidase catalyses the conversion of hypoxanthine to xanthine, uric acid and superoxide. This may be the one of the reasons for the elevated level of serum uric acid in ISO-treated rats in our investigation. Along with uric acid, generation of superoxide radicals leads to further increase in oxidative stress, which may be additive factor in myocardial necrosis produced by ISO. Swaminathan et al (26) revealed that C oxycantha significantly inhibited the activity of xanthine oxidase. In our study, C oxycantha-pretreated rats produced significant decrease in serum uric acid level after ISO administration, which may be due to inhibition of xanthine oxidase.

Sushamakumari et al (27) reported that ISO promotes tissue lipolysis. Enhancement in lipolysis and subsequent elevation of plasma free fatty acid (FFA) level may lead to an increased hepatic triglyceride

### Table 6

**Effect of *Crateagus oxycantha* on serum low-density lipoprotein (LDL) and very low-density LDL (VLDL) cholesterol, atherogenic index (ratio of LDL to high-density lipoprotein) and fecal cholesterol**

<table>
<thead>
<tr>
<th>Group</th>
<th>LDL, mmol/L</th>
<th>VLDL, mmol/L</th>
<th>Atherogenic index</th>
<th>Fecal cholesterol, mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.56±0.16</td>
<td>0.24±0.01</td>
<td>0.89±0.14</td>
<td>0.52±0.06</td>
</tr>
<tr>
<td>Control + <em>C. oxycantha</em> 50 mg/kg body weight orally</td>
<td>0.54±0.06</td>
<td>0.20±0.01</td>
<td>0.94±0.12</td>
<td>0.66±0.09</td>
</tr>
<tr>
<td>ISO (100 mg/kg)</td>
<td>1.03±0.12†</td>
<td>0.31±0.01*†</td>
<td>1.50±0.15*</td>
<td>0.54±0.04</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 25 mg/kg body weight orally)</td>
<td>0.78±0.05†</td>
<td>0.24±0.01†</td>
<td>1.32±0.13</td>
<td>0.89±0.09†</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 50 mg/kg body weight orally)</td>
<td>0.52±0.06†</td>
<td>0.19±0.01†</td>
<td>0.94±0.10†</td>
<td>1.10±0.09†</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD. *Significantly different from control (P<0.05); †Significantly different from isoproterenol (ISO)-treated group (P<0.05); ‡Significantly different from 50 mg/kg isoproterenol-pretreated rats (P<0.05).

### Table 7

**Effect of *Crateagus oxycantha* on lipid peroxidation, superoxide dismutase, catalase and reduced glutathione (GSH) levels**

<table>
<thead>
<tr>
<th>Group</th>
<th>Lipid peroxidation*</th>
<th>Superoxide dismutase†</th>
<th>Catalase‡</th>
<th>Reduced GSH§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>17.70±0.98</td>
<td>36.88±2.16</td>
<td>65.38±2.56</td>
<td>98.71±2.58</td>
</tr>
<tr>
<td>Control + <em>C. oxycantha</em> 50 mg/kg body weight orally</td>
<td>17.90±2.57</td>
<td>35.99±4.04</td>
<td>65.89±3.29</td>
<td>99.62±3.79</td>
</tr>
<tr>
<td>ISO (100 mg/kg)</td>
<td>39.78±1.45†</td>
<td>24.25±2.04†</td>
<td>42.05±2.15</td>
<td>75.05±2.74†</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 25 mg/kg body weight orally)</td>
<td>27.58±2.28**</td>
<td>33.44±2.79**</td>
<td>56.27±5.11**</td>
<td>86.04±5.47**</td>
</tr>
<tr>
<td>ISO (100 mg/kg + <em>C. oxycantha</em> 50 mg/kg body weight orally)</td>
<td>19.17±2.98††</td>
<td>36.65±3.38**</td>
<td>66.65±3.73††</td>
<td>100.03±8.33††</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD. *Expressed as nM malondialdehyde/g tissue; †Expressed as units/g tissue; ‡Expressed as μmol H2O2 consumed/min/g tissue; §Expressed as μg GSH/g tissue; †Expressed as μg GSH/g tissue; ‡Significantly different from control (P<0.05); §§Significantly different from isoproterenol (ISO)-treated group (P<0.05); ††Significantly different from 50 mg/kg isoproterenol-pretreated rats (P<0.05).
synthesis resulting in elevated plasma triglyceride and cholesterol levels. Manjula et al (28) reported the elevated level of cholesterol and triglyceride in ISO-induced myocardial damaged rats, which can be correlated with previous findings. It was reported earlier that hyperlipidemia is a prominent feature of ISO-induced cardiovascular disturbances (29,30). In the present study, serum cholesterol, triglyceride, LDL cholesterol, VLDL cholesterol and atherogenic index were significantly increased ISO-treated animals. Thus, our results can be clearly correlated with previous findings.

An excess of lipids in the circulation is considered to accelerate the development of atherosclerosis and is a risk factor for myocardial infarction. A strong positive correlation was well documented between the risk for developing ischemic heart disease and increased serum LDL cholesterol level. In the present investigation, C oxycantha produced significant decrease in serum levels of total cholesterol, triglyceride, LDL cholesterol and atherogenic index. Higher LDL to HDL ratio and atherogenic index are indicators of proatherosclerotic event. There was significant reduction in LDL to HDL ratio (atherogenic index) produced by C oxycantha in ISO-treated rats. This may be due to significant decrease in LDL cholesterol level by C oxycantha. Yuguang et al (31) reported that C oxycantha prevents cholesterol absorption by inhibiting enzyme Acyl CoA:cholesterol acetyl transferase (ACAT), which may be attributed to triterpenic acid-like ursolic acid present in the extract. Our HPTLC analysis also showed rich amounts of ursolic acid present in C oxycantha, which can be correlated with the above possible mechanism of its hypolipidemic activity. The unabsorbed cholesterol may be reflected in fecal matter. In our investigation, a dose-dependent significant increase in fecal cholesterol content was observed in ISO-treated rats pretreated with C oxycantha. Our results suggest that increased fecal cholesterol excretion may be attributed to inhibition of ACAT enzyme by virtue of presence of ursolic acid in C oxycantha.

It was demonstrated that catecholamine-like ISO increases generation of ROS via oxidation, which may lead to myocardial necrosis (32,33). LPO is one of the main manifestations of oxidative damage initiated by ROS and can be linked to the altered membrane structure and leakage of enzymes (34). In our study, a significant increase in LPO in terms of malondialdehyde was observed in ISO-treated rats, which suggests generation of oxidative stress by ISO and subsequent damage to myocardial membrane leading to release of enzymes, such as cTnl, CK-MB, LDH, SOD and GSH, into the serum. It was reported that C oxycantha is effective in quenching free radicals and inhibit LPO due to rich content of phenols and flavonoids (35,36). In our investigation, LPO was significantly prevented by pretreatment with C oxycantha in ISO-treated animals, which may be attributed to the presence of flavonoids and phenols in the extract.

Ashiq et al (23) reported that ISO-induced myocardial necrosis is associated with decreases in endogenous antioxidants such as SOD, catalase and GSH, resulting in myocardial damage. The present investigation also showed similar results. Subcutaneous ISO administration produced significant decrease in SOD, catalase and reduced GSH in myocardial tissue, which were restored to normal levels after pretreatment with C oxycantha. The increase in endogenous antioxidant activities in heart homogenate of rats pretreated with C oxycantha is an indication for myocardial structural integrity and protection to the myocardium, which may be responsible for cardioprotection.

Schwinger et al (37) demonstrated that Crataegus extract increased the force of contraction in left ventricular papillary muscle strips through a cAMP independent mechanism. It was suggested that Crataegus’s positive inotropic effect may also be due to inhibition of membrane-bound myocardial Na⁺/K⁺ ATPase, which maintains cardiac resting potential (38). It is also reported to have increased exercise tolerance during the early stage of congestive cardiac failure. The mechanism for cardiotonic activity of C oxycantha was proposed that ursolic acid of C oxycantha may interact with the digitaloid binding site of Na⁺/K⁺ ATPase enzyme and responsible for positive inotropic effect of C oxycantha (38). Our investigation demonstrated that C oxycantha significantly inhibits Na⁺-K⁺ ATPase enzyme present in heart homogenate, which may be attributed to ursolic acid present in the extract. Our results also suggest that Na⁺-K⁺ ATPase enzyme inhibiting activity of C oxycantha is comparable with the standard cardiotonic drug digoxin; however, in our investigation, digoxin (being a pure compound) was required in significantly lower amounts to produce inhibition of Na⁺-K⁺ ATPase compared with C oxycantha. On the other hand, Joseph et al (39) reported that digoxin and other cardioprotective drugs shorten the refractory period of the myocardium leading to increased risk for arrhythmias, while Crataegus prolongs the refractory phase, reducing the risk for arrhythmias. Blesken (40) suggested that Crataegus simultaneously exerts cardiotropic and vasodilatory action and, hence, can be safely and effectively used as a cardiotonic. The above findings suggest that C oxycantha may be safer and better option as a cardiotonic; however, further research is required to establish this.

Our research and previous findings, we propose that the cardiotonic effect of C oxycantha may be due to its ursolic acid content binding to digitalis site on the Na⁺-K⁺ ATPase enzyme. The HPTLC analysis of our C oxycantha extract exhibited the presence of ursolic acid. Thus, the cardiotonic effect of C oxycantha may be due to ursolic acid binding to digitoidal site and may be responsible for producing actions similar to digoxin.

CONCLUSION

Our data suggest that C oxycantha offers protection to the myocardium, as evidenced by maintaining serum cTn-I, CK-MB and other cardiac marker enzymes to nearly normal levels in ISO-treated rats. The histopathology of myocardial tissue further confirms the cardioprotective activity. The possible mechanism of cardiotonic activity of C oxycantha appears to be inhibition of myocardial Na⁺-K⁺ ATPase enzyme in isolated rat hearts, which may be attributed to presence of ursolic acid in the extract.

DISCLOSURES: None of the authors have actual or potential conflict of interest to disclose, including financial, personal or other relationships with specific persons or organizations.

REFERENCES


166 Curr Res Cardiol Vol 2 No 4 Winter 2015
27. Sushamakumari S, Varghese A, Muraleedharan D, Menon VP.
25. Weir CJ, Muir SW, Walters RM, Lees KR. Serum urate as an
24. Witteveen S, Hemkar HC, Hollar L, Hermens W. Quantitation of
23. Asdaq SMB, Inamdar MN, Asad M, Nanjundan PK. Interaction of
22. Rajadurai M, Stanely M. Preventive effect of naringin on cardiac
20. Choudhary R, Mishra KP, Subramanyam C. Prevention of
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac
18. Nirmala C, Puvanakrishnan R. Effect of curcumin on certain
17. Dhalla NS, Rupp H, Beamish RE, Bastos ML. Mechanisms of
16. Milei J, Nunez RG, Rapaport M. Pathogenesis of isoproterenol
15. Dhalla NS, Rupp H, Beamish RE, Bastos ML. Mechanisms of
14. Karthikeyan K, Saralabai BR, Devaraj N. Cardioprotective effect of
13. Wexler BC. Myocardial infarction in young versus old male rats:
12. Sakanaka S, Tachibana Y, Okada Y. Preparation and antioxidant